Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Completes M&A Bridge Re-Financing
December 25, 2018
- Mundipharma Files for Japan Approval of Anesthetic Remimazolam
December 25, 2018
- Kyoto Univ., Sumitomo Dainippon, Sumitomo Chemical Team Up for Research on iPS Cell Production
December 25, 2018
- Xtandi Smashes Primary Goal in Patients with mHSPC in PIII Trial
December 25, 2018
- Daiichi Sankyo Kicks Off 1st Combo Study for Its 2 AML Meds
December 21, 2018
- Fuji Pharma Invests US$50 Million in Alvotech to Boost Biosimilar Business in Japan
December 21, 2018
- ViiV’s HIV Drug Juluca Now Available in Japan
December 21, 2018
- Kowa Reps Continue Heavy GP Pitch for Parmodia in September: Anterio
December 21, 2018
- Taisho to Develop Overseas Biz in Asia and Europe through BMS’s Consumer Unit Buyout
December 21, 2018
- Fujifilm to Set Up New iPS Cell Production Facility in US, Start Operations in FY2019
December 21, 2018
- Life Science Institute Initiates Exploratory Clinical Trial of Muse Cell Product for Epidermolysis Bullosa
December 21, 2018
- Taisho to Acquire Bristol-Myers’s Consumer Health Unit
December 20, 2018
- Chugai’s Satralizumab Wins FDA Breakthrough Therapy Status
December 20, 2018
- ROS1/TRK Inhibitor Entrectinib Filed in Japan: Chugai
December 20, 2018
- Toray Sues Sawai, Fuso over Use Patent for Remitch OD Tablets
December 20, 2018
- Shionogi Licenses Cognitive Disorders Treatment Candidate from Tetra
December 20, 2018
- Shonan iPark Sets Up Consortium for Commercializing Disease Prevention
December 20, 2018
- Otezla Reduces Oral Ulcers in Japanese Behcet’s Disease Patients in PIII Study: Celgene
December 20, 2018
- Takeda Likely to Make NYSE Debut on Christmas Eve
December 19, 2018
- Bristol-Myers, Eisai Unit Ink I/O Collaboration
December 19, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…